Coherus BioSciences (CHRS) Tops Q3 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $0.85 +4.94%
EPS Growth %: +39.4%
Financial Fact:
Diluted net income/(loss) per share: 0.15
Today's EPS Names:
COHR, ATS, SICP, More
EPS Growth %: +39.4%
Financial Fact:
Diluted net income/(loss) per share: 0.15
Today's EPS Names:
COHR, ATS, SICP, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q3 EPS of ($0.27), $0.11 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $74.6 million versus the consensus estimate of $81.78 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Applovin shares surge on strong Q3 results and guidance
- Xperi Corporation (XPER) Tops Q3 EPS by 3c; Offers Guidance
- Wolfspeed (WOLF) Misses Q1 EPS by 147c; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
